3 results
Approved WMOCompleted
The objective of this trial is to evaluate the safety and efficacy of the combination of Fovista® intravitreous administration with Avastin® compared to Avastin® monotherapy.
Approved WMOCompleted
To directly correlate CLE images with histopathology, and identify and define CLE characteristics of normal urothelium, benign bladder urothelium, and bladder tumors (low-grade, high-grade NMIBC or CIS) of the lower urinary tract.
Approved WMOCompleted
To determine the Objective Response Rate (ORR) as assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 of CriPec® docetaxel monotherapy in subjects with ovarian cancer who are resistant to prior platinum-based therapy.